Exclusive Summary

• Targets a massive global market of over 200 million Atopic Dermatitis (AD) patients, addressing a high 20% pediatric prevalence with tremendous long-term demand.
• Features a highly desirable 'steroid-free' PDE4 inhibitor profile, perfectly suited for long-term maintenance in pediatrics (2+ years) and sensitive skin areas without corticosteroid side effects.
• Offers a disruptive cost advantage over the highly-priced originator (Eucrisa), unlocking massive market volume globally by significantly improving patient affordability and accessibility.
• Provides a ready-to-distribute solution with comprehensive regulatory support, enabling fast-track generic entry into emerging markets or strategic Day-1 launches upon patent cliffs in regulated regions.